A novel four-gene signature predicts immunotherapy response of patients with different cancers.

ABSTRACT:

Background

Immune checkpoint blockade (ICB) therapy has demonstrated favorable clinical efficacy, particularly for advanced or difficult-to-treat cancer types. However, this therapy is ineffective for many patients displaying lack of immune response or resistance to ICB. This study aimed to establish a novel four-gene signature (CD8A, CD8B, TCF7, and LEF1) to provide a prognostic immunotherapy biomarker for different cancers.

Methods

Transcriptome profiles and clinical data were obtained from The Cancer Genome Atlas database. Multivariate Cox regression analysis was used to establish a four-gene signature. The R package estimate was used to obtain the immune score for every patient.

Results

Risk scores of the novel four-gene signature could effectively divided all pat

SUBMITTER: Liu Y 

PROVIDER: S-EPMC9279975 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature